Brokerages expect Genenta Science S.p.A. (NASDAQ:GNTA – Get Rating) to post earnings per share of ($0.25) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Genenta Science’s earnings. The firm is expected to announce its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Genenta Science will report full-year earnings of ($1.05) per share for the current year. For the next fiscal year, analysts anticipate that the company will report earnings of ($0.91) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that cover Genenta Science.
GNTA has been the topic of a number of recent analyst reports. Maxim Group initiated coverage on Genenta Science in a research report on Thursday, January 13th. They set a “buy” rating and a $21.00 price target on the stock. Roth Capital reiterated a “buy” rating on shares of Genenta Science in a research report on Wednesday, January 12th.
About Genenta Science (Get Rating)
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
- Get a free copy of the StockNews.com research report on Genenta Science (GNTA)
- Hasbro Insider Bets Big On Stock Rebound
- The Coca-Cola Company Gets KO’d After Stunning Quarter
- Schwab Stock Can Be Caught Down Here
- Snap Up Some Snap-On On Post-Earnings Weakness
- Time to Buy any Dip in Prologis Stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genenta Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genenta Science and related companies with MarketBeat.com's FREE daily email newsletter.